文献速递神经肿瘤功能神经外科

免疫检查点抑制剂在儿童中枢神经系统肿瘤中的应用现状:系统综述及CMMRD相关胶质瘤代表性病例

The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma.
PubMed 文献 · J Neurooncol · 2025-11-03

汇总客观缓解率(ORR)为4.1%(95%CI:1.8-6.4),高级别胶质瘤(HGG)ORR为4.5%(95%CI:2.0-7.0),非HGG为3.6%(95%CI:1.0-6.5);双ICI/联合治疗≥3级免疫相关不良事件(irAE)发生率高达50%。结论认为ICI在儿童CNS肿瘤中获益有限,证据不足以支持常规临床使用。

要点

  • 儿童CNS肿瘤ICI汇总ORR仅4.1%,HGG为4.5%,非HGG为3.6%。
  • CMMRD/超突变HGG的ORR较高(10%),提示分子标志物选择价值。
  • 双ICI/联合治疗≥3级irAE可达50%,主要为皮疹、结肠炎和乏力。

核心结论

  • ICI在儿童CNS肿瘤中除特定分子定义亚组外获益有限,证据不足以支持常规临床使用。
  • 未来应强调生物标志物驱动的患者选择和联合治疗方案。

研究设计与样本

  • 系统综述检索截至2025年9月的多个数据库,纳入临床试验、回顾性队列和病例报告。
  • 8项研究(n=198,64%)以高级别胶质瘤(HGG)为主,其余(n=111,36%)包括髓母细胞瘤、室管膜瘤、ATRT及罕见肿瘤。
  • 疾病进展进行定量分析,其他终点采用描述性汇总。

主要发现

  • 汇总ORR为4.1%(95%CI:1.8-6.4),包括3例完全缓解和9例部分缓解。
  • 疾病稳定发生率为30.7%(n=67),常为暂时性;疾病进展常见。
  • HGG的ORR为4.5%(95%CI:2.0-7.0),PFS 1.5-6.2个月,OS 3.2-25.5个月。
  • 非HGG的ORR为3.6%(95%CI:1.0-6.5),PFS 2.1-4.5个月,OS 9.7-22.9个月。
  • CMMRD/超突变HGG的ORR较高(10%);双ICI/联合治疗≥3级irAE高达50%,主要为皮疹、结肠炎和乏力,无治疗相关死亡。

临床怎么用

  • 儿童CNS肿瘤不应常规使用ICI,需结合分子分型(如CMMRD/超突变)筛选潜在获益患者。
  • 双ICI或联合治疗时需警惕≥3级irAE(可达50%),重点监测皮疹、结肠炎和乏力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors (ICIs) have shown promise in adult oncology, but their role in pediatric central nervous system (CNS) tumors remains unclear. This systematic review evaluates the efficacy, safety, and clinical outcomes associated with ICI use in children and adolescents with primary CNS tumors, with the addition of a representative illustrative case to contextualize findings. METHODS: A systematic literature search was conducted across databases through September 2025 to identify studies reporting ICI use in pediatric CNS tumors. Eligible studies included clinical trials, retrospective cohorts, and case reports. Extracted data included patient demographics, tumor characteristics, treatment regimens, clinical outcomes, and adverse events. Disease progression was analyzed quantitatively; other endpoints were synthesized descriptively. RESULTS: Twelve studies with 309 pediatric CNS tumor patients (mean age 10.35 years, range 1-21; F/M ratio 0.8) using ICIs were analyzed. Eight studies (n = 198, 64%) predominantly included high-grade gliomas (HGGs); others (n = 111, 36%) included medulloblastoma, ependymoma, ATRT, and rare tumors. Pooled ORR was 4.1% (95% CI: 1.8-6.4), with 3 complete and 9 partial responses. Stable disease occurred in 30.7% (n = 67), often transient; progressive disease was common. HGG ORR was 4.5% (95% CI: 2.0-7.0), with PFS 1.5-6.2 months and OS 3.2-25.5 months. Non-HGG ORR was 3.6% (95% CI: 1.0-6.5), with PFS 2.1-4.5 months and OS 9.7-22.9 months. CMMRD/hypermutated HGGs had higher ORR (10%). Grade ≥3 irAEs occurred in up to 50% with dual ICI/combination therapy, mainly rash, colitis, and fatigue; no treatment-related deaths reported. CONCLUSIONS: In pediatric CNS tumors, ICIs provide limited benefit outside select molecularly defined subgroups. Although toxicities are generally manageable, evidence remains insufficient to support routine clinical use. Future efforts should emphasize biomarker-driven selection and combination regimens.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Gulsuna B, Lopez R, Kemp RDW, et al. The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma. J Neurooncol. 2025. PMID: 41182427. doi:10.1007/s11060-025-05241-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。